ABSTRACT
Status epilepticus (SE), the most severe form of epilepsy, leads to brain damage. Uncertainty persists about the mechanisms that lead to the pathophysiology of epilepsy and the death of neurons. Overloading of intracellular iron ions has recently been identified as the cause of a newly recognized form of controlled cell death called ferroptosis. Inhibiting ferroptosis has shown promise as a treatment for epilepsy, according to recent studies. So, the current study aimed to assess the possible antiepileptic impact of CoQ10 either alone or with the standard antiepileptic drug sodium valproate (SVP) and to evaluate the targeted effect of COQ10 on hippocampal oxidative stress and ferroptosis in a SE rat model. Using a lithium-pilocarpine rat model of epilepsy, we evaluated the effect of SVP, CoQ10, or both on seizure severity, histological, and immunohistochemical of the hippocampus. Furthermore, due to the essential role of oxidative stress and lipid peroxidation in inducing ferroptosis, we evaluated malonaldehyde (MDA), reduced glutathione (GSH), glutathione peroxidase 4 (GPX4), and ferritin in tissue homogenate. Our work illustrated that ferroptosis occurs in murine models of lithium-pilocarpine-induced seizures (epileptic group). Nissl staining revealed significant neurodegeneration. A significant increase in the number of astrocytes stained with an astrocyte-specific marker was observed in the hippocampus. Effective seizure relief can be achieved in the seizure model by administering CoQ10 alone compared to SVP. This was accomplished by lowering ferritin levels and increasing GPX4, reducing MDA, and increasing GSH in the hippocampus tissue homogenate. In addition, the benefits of SVP therapy for regulating iron stores, GPX4, and oxidative stress markers were amplified by incorporating CoQ10 as compared to SVP alone. It was concluded that CoQ10 alone has a more beneficial effect than SVP alone in restoring histological structures and has a targeted effect on hippocampal oxidative stress and ferroptosis. In addition, COQ10 could be useful as an adjuvant to SVP in protecting against oxidative damage and ferroptosis-related damage that result from epileptic seizures.
Subject(s)
Disease Models, Animal , Ferroptosis , Hippocampus , Status Epilepticus , Ubiquinone , Animals , Ferroptosis/drug effects , Status Epilepticus/drug therapy , Status Epilepticus/pathology , Status Epilepticus/chemically induced , Ubiquinone/analogs & derivatives , Ubiquinone/pharmacology , Ubiquinone/therapeutic use , Hippocampus/drug effects , Hippocampus/pathology , Hippocampus/metabolism , Rats , Male , Oxidative Stress/drug effects , Pilocarpine , Rats, Sprague-Dawley , Valproic Acid/pharmacology , Valproic Acid/therapeutic use , Lipid Peroxidation/drug effectsABSTRACT
Heterogeneity of Mesenchymal stem cells (MSCs) imposes limitations for their in vitro expansion and accounts for the lack of reproducibility in some clinical studies. So, this study was designed to isolate and enrich clones of multipotent and self-renewing MSCs from cord blood (CB). Enriched clones with higher proliferation and differentiation potential provide regenerative cells suitable for various clinical demands. MSCA and MSCB original (progenitor) cells were isolated from CB samples, and single cells were cloned by limiting dilution method, in mouse embryonic fibroblast conditioned media. Original MSCs and their single-cell derived clones were characterized by identifying their proliferation rate, immunophenotyping of surface antigens, expression of pluripotency and proliferation genes (Oct4, Sox2, Nanog, KLF4, c-Myc, and PDGFRA), and differentiation potential into multiple lineages (osteogenic, adipogenic, and chondrogenic). Some single-cell clones of MSCA showed a higher proliferation rate and greater differentiation potential than their original cells. However, original MSCB cells were of greater proliferation and differentiation potential than their derived single-cell clones, except for one clone which had comparable results. Cloning of MSCs was attainable when cultured in mouse embryonic fibroblast conditioned media. Single clones with higher proliferation and differentiation potential than their original progenitor cells were obtained by cloning of poorly functioning MSCs progenitor cells, enabling the selection of more therapeutically efficacious MSCs with better performance in clinical applications. Moreover, this study draws attention to the importance of CD105 as a possible MSCs biomarker associated with the multilineage commitment of MSCs.
Subject(s)
Cloning, Molecular/methods , Mesenchymal Stem Cell Transplantation/methods , Mesenchymal Stem Cells/metabolism , Adipogenesis/physiology , Cell Differentiation/physiology , Cell Proliferation/physiology , Cells, Cultured , Chondrogenesis/physiology , Fetal Blood/cytology , Humans , Immunophenotyping , Kruppel-Like Factor 4 , Reproducibility of Results , Umbilical Cord/cytologyABSTRACT
BACKGROUND: Occult hepatitis B virus infection (OBI) is a well-recognized clinical entity characterized by the detection of HBV DNA in serum and/or liver in the absence of detectable HBsAg. Diagnosis of OBI requires a sensitive HBV DNA assay. AIM: We aimed at determining the frequency of OBI in infants, born to HBsAg-positive mothers, who received immunoprophylaxis at birth. METHODS: Sixty-four infants and children, born to HBsAg-positive mothers, who received hepatitis B immunoglobulin and HBV vaccine within 48 h after birth, were tested for HBV serological profile and HBV DNA by real-time PCR at least 1 month after last dose of HBV vaccine and not before 6 months of age. RESULTS: The median age of the studied infants and children was 8 months, ranging from 6 to 132 months; 54.7 % were females. HBV DNA was detected in 2 infants. One case had OBI; she was negative for HBsAg, anti-HBc total, HBeAg and was positive for anti-HBs (titer 267 mIU/mL) with low level of viremia (HBV DNA 1.13 x 10(3) IU/mL). Another infant showed immunoprophylaxis failure with positive HBsAg, anti-HBc total, HBeAg, negative anti-HBe and anti-HBs; HBV viral load was 1.7 × 10(8) IU/mL. Both mothers were HBsAg and HBeAg-positive. CONCLUSION: OBI may occur in infants born to HBsAg-positive mothers despite the receipt of immunoprophylaxis. OBI was detected in a low frequency in the present study. Anti-HBs positivity does not exclude OBI.
Subject(s)
DNA, Viral/blood , Hepatitis B Surface Antigens/blood , Hepatitis B virus/isolation & purification , Hepatitis B/diagnosis , Hepatitis B/prevention & control , Immunization, Passive , Vaccination , Blood/virology , Child , Child, Preschool , Female , Hepatitis B/pathology , Humans , Infant , Infant, Newborn , Male , Prospective Studies , Real-Time Polymerase Chain Reaction , Viremia/diagnosisABSTRACT
Folic acid (FA), with its anti-inflammatory and antioxidant properties, may offer protection against ischemia-reperfusion (IR) injury. This study investigated whether FA safeguards rat kidneys from IR by targeting high mobility group box-1 (HMGB1), a key inflammatory mediator. Fifty adult male Wistar rats were randomly allocated into four groups: control, IR, IR + FA pretreatment, and FA alone. Compared to controls, IR significantly impaired renal function and elevated levels of malondialdehyde, HMGB1, NF-κB, and caspase 3. FA pretreatment effectively reversed these detrimental changes, protecting renal function and minimizing tissue damage. The FA-alone group showed no significant differences compared to the control group, indicating no adverse effects of FA treatment. Mechanistically, FA inhibited HMGB1 expression and its downstream activation of NF-κB and caspase 3, thereby quelling inflammation and cell death. FA shields rat kidneys from IR-induced injury by suppressing HMGB1-mediated inflammation and apoptosis, suggesting a potential therapeutic avenue for IR-associated kidney damage.
Subject(s)
HMGB1 Protein , Reperfusion Injury , Rats , Male , Animals , NF-kappa B/metabolism , NF-kappa B/pharmacology , Rats, Wistar , HMGB1 Protein/metabolism , HMGB1 Protein/pharmacology , Caspase 3 , Folic Acid/pharmacology , Inflammation/prevention & control , Kidney/metabolism , Reperfusion Injury/prevention & control , Reperfusion Injury/metabolism , Dietary Supplements , Reperfusion , IschemiaABSTRACT
This study assessed the levels of natural radionuclides (226Ra, 232Th, and 40K) and heavy metals (Hg, Fe, Cr, As, Zn, Cu, Cd, and Pb) in surface water and sediment samples from the Nile River in Qena Governorate, southern Egypt, using a gamma-ray spectrometer, 3" NaI (Tl) scintillation detector coupled with 1024 multi-channel analyzer, and an atomic absorption spectrometer. In surface water and sediments, the average activity concentrations of natural radionuclides were 40K (4.73 Bq L-1; 395.76 Bq kg-1) > 226Ra (0.41 Bq L-1; 18.14 Bq kg-1) > 232Th (0.30 Bq L-1; 17.98 Bq kg-1). The average heavy metal concentrations in surface water in µg L-1 were Fe (121.0) > Zn (33.80) > Cr (28.0) > Cu (8.62) > Pb (8.35) > As (1.19) > Hg (0.81) > Cd (0.12). In Nile sediments the concentrations in mg kg-1 were Fe (1670.0) > Zn (207.0) > Cr (29.40) > Cu (16.20) > Pb (4.32) > Hg (0.41) > Cd (0.31) > As (0.14). The heavy metal evaluation index (HMEI) calculations for water samples revealed that 31% of the samples were suitable for domestic use, while 69% were not. The geo-accumulation index, enrichment factor, and ecological risk factor for sediments were estimated, showing extreme enrichment for Hg and Zn with high ecological risk for Hg. Health risks for adults were evaluated due to oral and dermal exposure to Nile surface water and sediments from the study area, indicating minimal radiological risks and potential carcinogenic and non-carcinogenic risks from the metals.
Subject(s)
Mercury , Metals, Heavy , Water Pollutants, Chemical , Rivers , Cadmium , Water , Egypt , Lead , Geologic Sediments , Environmental Monitoring , Metals, Heavy/analysis , Radioisotopes , Water Pollutants, Chemical/analysis , Risk Assessment , ChinaABSTRACT
Mesenchymal stem cell (MSC)-based liver tissue engineering on nanofibrous scaffold holds great promise for cell-based therapy in liver injuries and end-stage liver failure treatments. MSCs were generated from umbilical cord blood. Hepatogenic differentiation was induced on two-dimensional (2D) and three-dimensional (3D) culture system and characterized by morphology, scanning electron microscopy, immunocytochemistry, and gene expression. Albumin and α-1 antitrypsin (AAT) in culture supernatants were measured. Differentiated cells were administered intravenous into a murine model of carbon tetra induced liver cirrhosis. After 12 weeks of injection, liver pathology was examined. The hepatogenic differentiated MSCs stained positively for albumin, alpha fetoprotein, HepPar1, cytokeratin 7 and 18, and OV6 with more mature cells, hexagonal in shape with central nuclei forming large sheets in groups in 3D culture system. AAT secretion and indocyanine green uptake were significantly increased in 3D system. In experimental model, MSC-3D treated group exhibited maximal restoration of liver architecture with absent septal fibrosis and marked improvement of alanine transaminase (ALT) and aspartate transaminase (AST), and mild increase in albumin. Both 3D and 2D culture system are effective in functional hepatogenic differentiation from MSCs and serve as a vehicle in liver tissue engineering. In vivo hepatogenic differentiation is more effective on 3D scaffold, with better functional recovery.
Subject(s)
Cell Differentiation , End Stage Liver Disease/therapy , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/cytology , Animals , Female , Fetal Blood/cytology , Hepatocytes/metabolism , Humans , Liver , Mesenchymal Stem Cells/metabolism , Mice , Mice, Inbred BALB C , Models, Theoretical , RegenerationABSTRACT
BACKGROUND AND STUDY AIMS: Mother-infant hepatitis B virus (HBV) transmission is the current leading cause of chronic infection. We aimed to assess the efficacy of lamivudine use in hepatitis B surface antigen (HBsAg)-positive pregnant women to decrease viral load and thus aid in the prevention of transmission. PATIENTS AND METHODS: A study of 73 mother-infant pairs. All mono-infected HBsAg-positive pregnant females of any age, who were a candidate for lamivudine during pregnancy were recruited, and a comparison group of HBsAg-positive pregnant females who did not receive any antiviral treatment. All infants received HBV immunoglobulin and vaccine at birth and completed the vaccination schedule and tested after 6â¯months of age. HBV viral markers and viral load quantitation were performed to all enrolled participants. RESULTS: 34 (46.6%) females were enrolled in the lamivudine group; 9 (26.5%) received the drug in the last trimester, 25 (73.5%) all through. The comparison group was 39 (53.4%) females; 32 (82.1%) were not candidate for antiviral during pregnancy, and 7 (17.9%) were diagnosed late near delivery. Seventy-one infants tested after full immunization, with their ages ranged between 6.5 and 18â¯months. Only one infant (1.4%) was positive for HBsAg and HBV DNA in the non-treated group. Maternal viremia near delivery showed a significant reduction in cases that used lamivudine during pregnancy. CONCLUSION: The use of lamivudine during pregnancy can effectively lower maternal viral load. Timely conducted post-vaccination serological testing is crucial to detect positive cases and immunize susceptible infants.
Subject(s)
Hepatitis B/drug therapy , Hepatitis B/transmission , Infectious Disease Transmission, Vertical/prevention & control , Lamivudine/therapeutic use , Pregnancy Complications, Infectious/drug therapy , Reverse Transcriptase Inhibitors/therapeutic use , Adult , DNA, Viral/blood , Female , Hepatitis B/blood , Hepatitis B Surface Antigens/blood , Hepatitis B Vaccines , Hepatitis B virus/genetics , Humans , Immunoglobulins , Infant , Infant, Newborn , Pregnancy , Pregnancy Complications, Infectious/blood , Prospective Studies , Vaccination , Viral Load/drug effects , Viremia/drug therapy , Viremia/virology , Young AdultABSTRACT
Mesenchymal stem cells (MSCs) therapy show different levels of effectiveness in the context of different types of liver damage, suggesting that the microenvironment of the injured liver is a key determinant for effective stem cell therapy. The objective was to assess the modulatory effect of hepatic stem cell niche components on the transplanted MSCs during liver injury induced by carbon tetrachloride (CCl4). Superparamagnetic iron oxide (SPIO)-labeled human MSCs were injected intravenously into mice treated with CCl4 and subjected to hepatic macrophage-depletion. Liver tissues were collected at different intervals post transplantation for subsequent histopathological, morphometric, immunohistochemical, gene expression and ultrastructural studies. The homing of the transplanted MSCs was evidenced by tracing them within the niche by iron staining and immunohistochemical studies. MSCs differentiated into hepatocyte-like cells and intimal smooth muscle cells as evidenced by their expression of human albumin and α-smooth muscle actin with a concomitant increase in the level of mouse hepatocyte growth factor. A post transplantation reduction in the liver fibro-inflammatory reaction was found and was promoted by liver macrophages depletion. Thus, it could be concluded from the present study that prior manipulation of the microenvironment is required to improve the outcome of the transplanted cells.
Subject(s)
Chemical and Drug Induced Liver Injury/pathology , Chemical and Drug Induced Liver Injury/therapy , Macrophages/immunology , Mesenchymal Stem Cell Transplantation , Animals , Biometry , Carbon Tetrachloride/administration & dosage , Carbon Tetrachloride/toxicity , Disease Models, Animal , Gene Expression Profiling , Histocytochemistry , Immunohistochemistry , Mice , Treatment OutcomeABSTRACT
The present study was designed to identify the chemical constituents of the methanolic extract of Curcuma longa L. rhizomes and their inhibitory effect on a hepatoma cell line. The methanolic extract was subjected to GC-MS analysis to identify the volatile constituents and the other part of the same extract was subjected to liquid column chromatographic separation to isolate curcumin. The inhibition of cell growth in the hepatoma cell line and the cytopathological changes were studied. GC-MS analysis showed the presence of fifty compounds in the methanolic extract of C. longa. The major compounds were ar-turmerone (20.50 %), ß-sesquiphellandrene (5.20 %) and curcumenol (5.11 %). Curcumin was identified using IR, 1H and 13C NMR. The inhibition of cell growth by curcumin (IC50 = 41.69 ± 2.87 µg mL-1) was much more effective than that of methanolic extract (IC50 = 196.12 ± 5.25 µg mL-1). Degenerative and apoptotic changes were more evident in curcumin- treated hepatoma cells than in those treated with the methanol extract. Antitumor potential of the methanolic extract may be attributed to the presence of sesquiterpenes and phenolic constituents including curcumin (0.051 %, 511.39 µg g-1 dried methanol extract) in C. longa rhizomes.
Subject(s)
Antineoplastic Agents, Phytogenic/chemistry , Apoptosis/drug effects , Carcinoma, Hepatocellular/drug therapy , Curcuma/chemistry , Drug Discovery , Liver Neoplasms/drug therapy , Plant Extracts/chemistry , Volatile Organic Compounds/analysis , Antineoplastic Agents, Phytogenic/analysis , Antineoplastic Agents, Phytogenic/isolation & purification , Antineoplastic Agents, Phytogenic/pharmacology , Carcinoma, Hepatocellular/pathology , Cell Proliferation/drug effects , Cell Survival/drug effects , Chromatography, High Pressure Liquid , Chromatography, Liquid , Curcumin/analysis , Curcumin/isolation & purification , Curcumin/pharmacology , Cyclohexane Monoterpenes , Cyclohexenes/analysis , Cyclohexenes/isolation & purification , Gas Chromatography-Mass Spectrometry , Hep G2 Cells , Humans , Inhibitory Concentration 50 , Ketones/analysis , Ketones/isolation & purification , Liver Neoplasms/pathology , Monoterpenes/analysis , Monoterpenes/isolation & purification , Plant Extracts/isolation & purification , Plant Extracts/pharmacology , Rhizome/chemistry , Sesquiterpenes/analysis , Sesquiterpenes/isolation & purification , Sesquiterpenes/pharmacology , Volatile Organic Compounds/isolation & purificationABSTRACT
BACKGROUND/AIMS: An association of type 1 DM and familial Mediterranean fever (FMF) has been newly reported in the medical literature. The aim of the present work was to investigate frequency of MEFV gene mutations in Egyptian children with type 1 diabetes mellitus. METHODS: Forty five children with type 1 DM were screened for Mediterranean Fever (MEFV) gene mutation. Forty one healthy control subjects were included. Identification of FMF gene mutation was done based on polymerase chain reaction (PCR) and reverse hybridization. The assay covers 12 mutations in the FMF gene: E148Q - P369S - F479L - M680I (G/C) - M680I (G/A) - I692del - M694V - M694I - K695R-V726A - A744S and R761H. RESULTS: Among the screened diabetics, the overall frequency of MEFV gene mutations was 42.2% and among the control group it was 34.1% with no significant difference. Fourteen out of 45 diabetic children (31.1%) were heterozygous (E148Q in 7 children, A744S in 3 children, V726A in 2 children, M680I (G/C) in 1 child and P369S in1 child), while 5 children (11.1%) were compound heterozygous (M694V/M694I in 2 children, E148Q/K695R mutations in 1 child, E148Q/M694I in 1 child and E148Q/V726A in 1 child). The control group showed heterozygous mutation in 34.1% of cases (E148Q mutation in 14.6%, V726A in 12.2%, M680I (G/C) in 4.9% and M694V in 2.4%). CONCLUSION: No significant difference in mutation frequency between diabetic and non-diabetic children. We have high carrier rate of MEFV gene mutations among Egyptian population probably due to high consanguinity.
Subject(s)
Cytoskeletal Proteins/genetics , Diabetes Mellitus, Type 1/genetics , Familial Mediterranean Fever/genetics , Mutation , Adolescent , Child , Child, Preschool , Diabetes Mellitus, Type 1/epidemiology , Egypt/epidemiology , Familial Mediterranean Fever/epidemiology , Female , Humans , Male , PyrinABSTRACT
BACKGROUND: This research was carried out to develop a reliable monoclonal antibody (MoAb)-based sandwich enzyme linked immunosorbent assay (ELISA) for the diagnosis of active Fasciola gigantica infection in both serum and stool for comparative purposes. METHODS: From a panel of MoAbs raised against F. gigantica excretory/secretory antigens (ES Ags), a pair (12B/11D/3F and 10A/9D/10G) was chosen due to its high reactivity and strict specificity to F. gigantica antigen by indirect ELISA. RESULTS: The two MoAbs were of the IgG1 and IgG(2a) subclasses, respectively. Using SDS-PAGE and EITB, the selected MoAbs recognized 83, 64, 45 and 26 kDa bands of ES Ags. The lower detection limit of ELISA assay was 3 ng/ml. In stool, the sensitivity, specificity and diagnostic efficacy of ELISA was 96%, 98.2 and 97.1%; while in serum they were 94%, 94.6% and 94.3%, respectively. Moreover, a positive correlation was found between ova count in stool of F. gigantica infected patients and the OD readings of ELISA in both stool and serum samples (r = 0.730, p < 0.01 and r = 0.608; p < 0.01, respectively). CONCLUSIONS: These data showed that the use of MoAb-based sandwich ELISA for the detection of F. gigantica coproantigens in stool specimens was superior to serum samples; it provides a highly efficient, non-invasive technique for the diagnosis of active F. gigantica infection.